PRESSURE BIOSCIENCES, INC.: net income available to common stockholders
Net income available to common stockholders for PRESSURE BIOSCIENCES, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All PRESSURE BIOSCIENCES, INC. financial histories
What this measure means
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
Exact concept: us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-01-01 to 2023-12-31. The SEC response was captured on 2026-09-21.
This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2023-01-01 | 2023-12-31 | -35,202,434 | USD | 2024-06-07 | 10-K · 0001493152-24-023201 |
| 2022-01-01 | 2022-12-31 | -17,803,953 | USD | 2024-06-07 | 10-K · 0001493152-24-023201 |
| 2021-01-01 | 2021-12-31 | -22,685,459 | USD | 2023-04-12 | 10-K · 0001493152-23-012010 |
| 2020-01-01 | 2020-12-31 | -17,584,710 | USD | 2022-04-05 | 10-K · 0001493152-22-009156 |
| 2019-01-01 | 2019-12-31 | -15,868,083 | USD | 2021-04-15 | 10-K · 0001493152-21-008950 |
| 2018-01-01 | 2018-12-31 | -23,473,150 | USD | 2020-04-14 | 10-K · 0001493152-20-006406 |
| 2017-01-01 | 2017-12-31 | -10,715,561 | USD | 2019-04-16 | 10-K · 0001493152-19-005470 |
| 2016-01-01 | 2016-12-31 | -2,706,984 | USD | 2017-03-22 | 10-K · 0001493152-17-002726 |
| 2015-01-01 | 2015-12-31 | -7,438,492 | USD | 2017-03-22 | 10-K · 0001493152-17-002726 |
| 2014-01-01 | 2014-12-31 | -6,251,726 | USD | 2016-04-05 | 10-K · 0001493152-16-008655 |
| 2013-01-01 | 2013-12-31 | -5,247,449 | USD | 2015-03-31 | 10-K · 0001354488-15-001522 |
| 2012-01-01 | 2012-12-31 | -4,400,215 | USD | 2014-03-31 | 10-K · 0001354488-14-001538 |
| 2011-01-01 | 2011-12-31 | -5,107,661 | USD | 2013-05-13 | 10-K · 0001354488-13-002661 |
| 2010-01-01 | 2010-12-31 | -3,630,826 | USD | 2012-02-27 | 10-K · 0000830656-12-000016 |
Related financial histories
- PRESSURE BIOSCIENCES, INC.: total assets
- PRESSURE BIOSCIENCES, INC.: total liabilities
- PRESSURE BIOSCIENCES, INC.: stockholders equity
- PRESSURE BIOSCIENCES, INC.: cash and cash equivalents
- PRESSURE BIOSCIENCES, INC.: net income or loss
- PRESSURE BIOSCIENCES, INC.: operating cash flow
- PRESSURE BIOSCIENCES, INC.: capital expenditure payments
- PRESSURE BIOSCIENCES, INC.: revenue
- PRESSURE BIOSCIENCES, INC.: contract revenue excluding tax
- PRESSURE BIOSCIENCES, INC.: financing cash flow
- PRESSURE BIOSCIENCES, INC.: investing cash flow
- PRESSURE BIOSCIENCES, INC.: retained earnings or deficit
- PRESSURE BIOSCIENCES, INC.: basic weighted-average shares
- PRESSURE BIOSCIENCES, INC.: basic earnings per share
- PRESSURE BIOSCIENCES, INC.: income tax expense or benefit
- PRESSURE BIOSCIENCES, INC.: net property, plant and equipment
- PRESSURE BIOSCIENCES, INC.: share-based compensation expense
- PRESSURE BIOSCIENCES, INC.: operating income or loss
- PRESSURE BIOSCIENCES, INC.: current assets
- PRESSURE BIOSCIENCES, INC.: interest expense
- PRESSURE BIOSCIENCES, INC.: current liabilities
- PRESSURE BIOSCIENCES, INC.: current accounts payable
- PRESSURE BIOSCIENCES, INC.: net finite-lived intangible assets
- PRESSURE BIOSCIENCES, INC.: net current accounts receivable
- PRESSURE BIOSCIENCES, INC.: operating expenses
- PRESSURE BIOSCIENCES, INC.: net inventory
- PRESSURE BIOSCIENCES, INC.: research and development expense
- PRESSURE BIOSCIENCES, INC.: common shares outstanding
- PRESSURE BIOSCIENCES, INC.: additional paid-in capital
- PRESSURE BIOSCIENCES, INC.: total equity including noncontrolling interests
- PRESSURE BIOSCIENCES, INC.: operating lease right-of-use asset
- PRESSURE BIOSCIENCES, INC.: operating lease liability
- PRESSURE BIOSCIENCES, INC.: long-term debt
- PRESSURE BIOSCIENCES, INC.: gross property, plant and equipment
- PRESSURE BIOSCIENCES, INC.: accumulated depreciation on property, plant and equipment
- PRESSURE BIOSCIENCES, INC.: net intangible assets excluding goodwill
- PRESSURE BIOSCIENCES, INC.: accrued current liabilities
- PRESSURE BIOSCIENCES, INC.: prepaid expenses and other current assets
- PRESSURE BIOSCIENCES, INC.: current contract liabilities
- PRESSURE BIOSCIENCES, INC.: profit or loss including noncontrolling interests
- PRESSURE BIOSCIENCES, INC.: comprehensive income or loss
- PRESSURE BIOSCIENCES, INC.: general and administrative expense
- PRESSURE BIOSCIENCES, INC.: depreciation expense
- PRESSURE BIOSCIENCES, INC.: depreciation, depletion and amortization
- PRESSURE BIOSCIENCES, INC.: amortization of intangible assets
- PRESSURE BIOSCIENCES, INC.: nonoperating income or expense
- PRESSURE BIOSCIENCES, INC.: interest paid, net
- PRESSURE BIOSCIENCES, INC.: proceeds from issuing common stock
- PRESSURE BIOSCIENCES, INC.: change in accounts receivable
- PRESSURE BIOSCIENCES, INC.: change in inventories
- PRESSURE BIOSCIENCES, INC.: change in accounts payable
Inspect the source
- Entity
- PRESSURE BIOSCIENCES, INC. / CIK 0000830656
- Captured
- 2026-09-21T17:17:15.791Z
- SEC response SHA-256
9f53d6670ff4d2eff56cabbc6920a9205a8540e6e5042ac9d3ad7d038501b96e
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000830656.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))